Eckert & Ziegler SE is a global provider of isotope technology components, serving the medical, scientific, and industrial sectors. The company's business model centers on the processing of radioisotopes and the development, production, and sale of related components, alongside contract manufacturing services.
Revenue is primarily generated through two main operating segments: Medical and Isotope Products. The Medical segment, which accounts for approximately 55% of total revenue, provides pharmaceutical-quality radioactive ingredients, small radioactive implants for treating prostate cancer (brachytherapy seeds), eye applicators for treating uveal melanoma, and contract manufacturing services for the radiopharmaceutical industry. Key products in this segment include gallium generators and actinium-225, which are utilized in targeted radiotherapy and nuclear medicine. The Isotope Products segment, contributing roughly 45% of revenue, manufactures and distributes standards and radiation sources for medical and industrial purposes. This includes calibration sources for medical imaging, industrial gauging, and environmental monitoring.
Geographically, Eckert & Ziegler has an international footprint. Europe is its largest market, generating the majority of its sales, but the company also maintains significant operations and production facilities in North America, South America, and Asia, including recent facility expansions in China and the United States. The company maintains its competitive position through strategic partnerships with major pharmaceutical companies for radioisotope production and contract manufacturing, securing its role as a supplier in the radiopharmaceutical supply chain.
